TY - JOUR AU - Watanabe, Satoshi AU - Saeki, Keigo AU - Waseda, Yuko AU - Murata, Akari AU - Takato, Hazuki AU - Ichikawa, Yukari AU - Yasui, Masahide AU - Kimura, Hideharu AU - Hamaguchi, Yasuhito AU - Matsushita, Takashi AU - Yamada, Kazunori AU - Kawano, Mitsuhiro AU - Furuichi, Kengo AU - Wada, Takashi AU - Kasahara, Kazuo PY - 2018 TI - Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes JF - Journal of Thoracic Disease; Vol 10, No 2 (February 14, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Backgrounds: Lung cancer (LC) adversely impacts survival in patients with idiopathic pulmonary fibrosis. However, little is known about LC in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). The aim of this study was to evaluate the prevalence of and risk factors for LC in CTD-ILD, and the clinical characteristics and survival of CTD-ILD patients with LC. Methods: We conducted a single-center, retrospective review of patients with CTD-ILD from 2003 to 2016. Patients with pathologically diagnosed LC were identified. The prevalence, risk factors, and clinical features of LC and the impact of LC on CTD-ILD patient outcomes were observed. Results: Of 266 patients with CTD-ILD, 24 (9.0%) had LC. CTD-ILD with LC was more likely in patients who were older, male, and smokers; had rheumatoid arthritis, a usual interstitial pneumonia pattern, emphysema on chest computed tomography scan, and lower diffusing capacity of the lung carbon monoxide (DLco)% predicted; and were not receiving immunosuppressive therapy. Multivariate analysis indicated that the presence of emphysema [odds ratio (OR), 8.473; 95% confidence interval (CI), 2.241–32.033] and nonuse of immunosuppressive therapy (OR, 8.111; 95% CI, 2.457–26.775) were independent risk factors for LC. CTD-ILD patients with LC had significantly worse survival than patients without LC (10-year survival rate: 28.5% vs . 81.8%, P Conclusions: LC is associated with the presence of emphysema and nonuse of immunosuppressive therapy, and contributes to increased mortality in patients with CTD-ILD. UR - https://jtd.amegroups.org/article/view/18417